Integer (NYSE:ITGR) Downgraded to “Market Perform” Rating by Oppenheimer

Oppenheimer cut shares of Integer (NYSE:ITGR) from an outperform rating to a market perform rating in a research note issued to investors on Friday, MarketBeat reports.

A number of other research firms have also weighed in on ITGR. Piper Sandler reaffirmed an “overweight” rating and issued a $140.00 price objective (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. Wells Fargo & Company reissued an “overweight” rating and issued a $160.00 target price on shares of Integer in a report on Tuesday, December 3rd. Truist Financial raised their target price on shares of Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. KeyCorp boosted their price target on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Finally, Citigroup raised their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Integer has an average rating of “Moderate Buy” and an average target price of $147.67.

Integer Stock Down 3.9 %

NYSE ITGR opened at $129.96 on Friday. Integer has a 52 week low of $98.63 and a 52 week high of $146.36. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $4.36 billion, a P/E ratio of 40.11, a price-to-earnings-growth ratio of 1.82 and a beta of 1.13. The stock’s 50-day moving average price is $137.92 and its 200-day moving average price is $132.31.

Integer (NYSE:ITGR) last released its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The firm had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. On average, equities research analysts predict that Integer will post 5.33 earnings per share for the current year.

Institutional Trading of Integer

A number of large investors have recently made changes to their positions in ITGR. Creative Planning lifted its holdings in shares of Integer by 22.2% in the 3rd quarter. Creative Planning now owns 9,077 shares of the medical equipment provider’s stock worth $1,180,000 after acquiring an additional 1,650 shares during the last quarter. First Trust Direct Indexing L.P. purchased a new position in shares of Integer during the third quarter valued at $215,000. Congress Asset Management Co. raised its holdings in shares of Integer by 3.9% in the third quarter. Congress Asset Management Co. now owns 488,785 shares of the medical equipment provider’s stock valued at $63,542,000 after acquiring an additional 18,303 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Integer by 1.0% in the third quarter. New York State Common Retirement Fund now owns 192,411 shares of the medical equipment provider’s stock worth $25,013,000 after acquiring an additional 1,820 shares during the period. Finally, James Investment Research Inc. lifted its stake in Integer by 7.2% in the third quarter. James Investment Research Inc. now owns 12,290 shares of the medical equipment provider’s stock worth $1,598,000 after acquiring an additional 824 shares during the period. 99.29% of the stock is currently owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.